NEW YORK (GenomeWeb) – Biocept announced today that it has signed agreements to sell $9.3 million in stock and warrants to certain institutional investors.

According to the company, it will sell about 4.3 million shares of its common stock at $2.15 per share, as well as warrants to purchase up to roughly 2.2 million shares of common stock at an exercise price of $2.50 a share. The warrants are exercisable six months after the close of the transaction and expire five years from the date they become exercisable.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.

Sep
18
Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.